I called Liminal BioSciences Inc (NASDAQ:LMNL) recently at $4.40 as a potential big runner due to the PDUFA catalyst. On Friday, just a few minutes before the close, the stock was halted and the U.S. Food & Drug Administration (FDA) announced the approval of Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen...
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs